Disposition of leucovorin and its metabolites in dietary folic acid-deplete mice – comparison between tumor, liver and plasma |
| |
Authors: | K Raghunathan John C Schmitz D G Priest |
| |
Institution: | (1) Department of Biochemistry and Molecular Biology, Medical University of South Carolina, 171 Ashley Avenue, Charleston, South Carolina 29425-2211, USA Tel. (803)-792-4321; Fax (803)-792-4322, US |
| |
Abstract: | Purpose: A comprehensive pharmacokinetic study of leucovorin (5-formyltetrahydrofolate, 5-HCO-FH4) and its metabolites was conducted in plasma, liver and implanted tumor tissue from mice maintained on a low folic acid diet.
While it has been previously demonstrated that the antitumor activity of fluorouracil (FU) can be potentiated by 5-HCO-FH4, the optimum time for administration of FU after 5-HCO-FH4, to maximally elevate the active folate metabolite methylenetetrahydrofolate in tumor has not been established. Human plasma
studies have defined the pharmacokinetics of circulating 5-HCO-FH4 and its metabolites, but comparison with human tumor accumulation has not been practicable because of sampling difficulties.
As an alternative, a mouse model system, based on low dietary folic acid, was used to evaluate plasma, liver and implanted
tumor reduced folates after administration of 5-HCO-FH4.Methods: Plasma and tissue samples were collected from folate-deplete mice over a 12-h period after intraperitoneal administration
of 90 mg/kg R, S ] 5-HCO-FH4. Reduced folates were evaluated using a ternary complex assay. Results: The time at which max‐imal accumulation of parent compound and all metabolites, except 5-methyltetrahydrofolate (5-CH3FH4), occurred in tumor was the same as in plasma. Alternatively, peak liver accumulation was delayed relative to plasma for
all folates except 5-CH3FH4. Conclusions: The results suggest that mouse plasma accumulation of reduced folates, with the exception of 5-CH3FH4, can predict tumor accumulation. Hence, evaluation of human plasma folate accumulation may potentially provide a means to
improve the timing of the administration of FU relative to 5-HCO-FH4 to achieve a superior therapeutic outcome.
Received: 24 July 1996 / Accepted: 29 October 1996 |
| |
Keywords: | Reduced folates Pharmacokinetics Leucovorin C3H mice C3H mammary adenocarcinoma |
本文献已被 SpringerLink 等数据库收录! |
|